Other
coMMit, Myeloma Trials, Innovated
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
2 recruiting
Enrollment Performance
Analytics
Phase 2
2(100.0%)
2Total
Phase 2(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT06974786Phase 2Recruiting
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Role: collaborator
NCT05231629Phase 2Recruiting
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Role: collaborator
All 2 trials loaded